Results 211 to 216 of about 37,430 (216)

Treatment with lenalidomide induces immunoactivating and counter-regulatory immunosuppressive changes in myeloma patients.

Clinical and Experimental Immunology, 2014
P Brossart
exaly  

No clinically significant drug interactions between lenalidomide and P-glycoprotein substrates and inhibitors: results from controlled phase I studies in healthy volunteers

Cancer Chemotherapy and Pharmacology, 2014
Maria Palmisano, Simon Zhou, Nianhang Chen   +2 more
exaly  

Thalidomide and lenalidomide: Mechanism-based potential drug combinations

Leukemia and Lymphoma, 2008
Mario Boccadoro, Antonio Palumbo, Noopur Raje   +2 more
exaly  

Ibrutinib plus lenalidomide and rituximab has promising activity in relapsed/refractory non–germinal center B-cell–like DLBCL

Blood, 2019
Andre H Goy, Nam H Dang, Darrin M Beaupré   +2 more
exaly  

A phase I/II study of lenalidomide in combination with sunitinib in patients with advanced or metastatic renal cell carcinoma

Annals of Oncology, 2014
J R Infante, H A Burris, B Redman
exaly  

Lenalidomide

Reactions Weekly, 2012
openaire   +2 more sources